# Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

> **NCT05352672** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 1546 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Fianlimab
- **DRUG:** Cemiplimab
- **DRUG:** Pembrolizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05352672
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-14
- **Primary completion:** 2026-03-12
- **Final completion:** 2031-09-16
- **Target enrollment:** 1546 (ACTUAL)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05352672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05352672, "Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05352672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*